Ondansetron 2 mg/ml solution for injection/infusion
Authorisation PA2165/013/001 · AS Kalceks
- Licence holder
- AS Kalceks (all products →)
- Active substance
- Ondansetron
- Clinical trials
- 20 clinical trials →
- Dosage form
- Solution for injection/infusion
- Routes of administration
- Intramuscular use, Intravenous use
- ATC code
- A04AA01
- First authorised
- 08/10/2021
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Generic application (Article 10(1) of Directive No 2001/83/EC)
Ondansetron: supply and approvals
27 authorised products on the HPRA list contain Ondansetron. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 21 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 21 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 21 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 5 years (since 8 October 2021). The HPRA list marks it as marketed in Ireland.
Other medicines with Ondansetron in Ireland
23 other products on the HPRA list contain Ondansetron, from 13 licence holders; 17 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Emizof 4 mg film-coated tablets | Viatris Limited | National authorisation (PA) | Marketed |
| Emizof 8 mg film-coated tablets | Viatris Limited | National authorisation (PA) | Marketed |
| Ondansetron 2 mg/ml Solution for Injection | Noridem Enterprises Limited | National authorisation (PA) | Marketed |
| Ondansetron 2 mg/ml Solution for Injection or Infusion | Viatris Limited | National authorisation (PA) | Marketed |
| Ondansetron 2 mg/ml Solution for Injection or Infusion | Accord Healthcare Ireland Ltd. | National authorisation (PA) | Marketed |
| Ondansetron 2mg/ml Solution for Injection | Baxter Holding B.V. | National authorisation (PA) | Marketed |
| Ondansetron 4 mg film-coated tablets | Teva Pharma B.V. | National authorisation (PA) | Marketed |
| Ondansetron 4 mg/5 ml syrup | Syri Pharma Limited t/a Thame Laboratories | National authorisation (PA) | Marketed |
| Ondansetron 8 mg film-coated tablets | Teva Pharma B.V. | National authorisation (PA) | Marketed |
| Ondansetron Kabi 2 mg/ml solution for injection | Fresenius Kabi Deutschland GmbH | National authorisation (PA) | Marketed |
| Ondran 4 mg film-coated tablets | Pinewood Laboratories Ltd | National authorisation (PA) | Marketed |
| Ondran 8 mg film-coated tablets | Pinewood Laboratories Ltd | National authorisation (PA) | Marketed |
The licence holder
AS Kalceks holds 29 products on the HPRA list, with 23 different active substances; 16 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.